(Q37149382)

18 August 2017

1 reference

title

Advanced glycation end products and diabetic foot disease (English)

1 reference

18 August 2017

Maya S P Huijberts

1 reference

18 August 2017

Nicolaas C Schaper

series ordinal

1 reference

18 August 2017

Casper G Schalkwijk

series ordinal

1 reference

18 August 2017

publication date

1 May 2008

1 reference

Diabetes - Metabolism: Research and Reviews

18 August 2017

published in

1 reference

18 August 2017

volume

24 Suppl 1

1 reference

18 August 2017

page(s)

S19-24

1 reference

The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation

18 August 2017

cites work

1 reference

The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis

21 January 2018

1 reference

Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily

21 January 2018

1 reference

Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice.

21 January 2018

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

7 January 2021

The pathobiology of diabetic complications: a unifying mechanism

1 reference

7 January 2021

The global burden of diabetic foot disease

1 reference

7 January 2021

World Diabetes Day: footing the bill

1 reference

7 January 2021

Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy

1 reference

7 January 2021

BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells

1 reference

7 January 2021

Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes

1 reference

7 January 2021

Glucose and diabetic vascular disease.

1 reference

7 January 2021

Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification

1 reference

7 January 2021

Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins

1 reference

7 January 2021

Formation of methylglyoxal and D-lactate in human red blood cells in vitro

1 reference

7 January 2021

Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis

1 reference

7 January 2021

Advanced glycation end-products: a review

1 reference

7 January 2021

Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options

1 reference

7 January 2021

Advanced glycation endproducts--role in pathology of diabetic complications

1 reference

7 January 2021

Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE

1 reference

7 January 2021

Atherogenesis and advanced glycation: promotion, progression, and prevention

1 reference

7 January 2021

Advanced glycation end-products and atherosclerosis

1 reference

7 January 2021

Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism.

1 reference

7 January 2021

Alzheimer's disease: inside, outside, upside down.

1 reference

7 January 2021

Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes

1 reference

7 January 2021

Scavenger receptors that recognize advanced glycation end products

1 reference

7 January 2021

RAGE: a novel cellular receptor for advanced glycation end products

1 reference

7 January 2021

Understanding RAGE, the receptor for advanced glycation end products

1 reference

7 January 2021

Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB

1 reference

7 January 2021

The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site

1 reference

7 January 2021

Activation of the Receptor for Advanced Glycation End Products Triggers a p21 -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress

1 reference

7 January 2021

High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study

1 reference

7 January 2021

Trapped immunoglobulins on peripheral nerve myelin from patients with diabetes mellitus

1 reference

7 January 2021

Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats

1 reference

7 January 2021

Receptor for Advanced Glycation End Products Activation Injures Primary Sensory Neurons via Oxidative Stress

1 reference

7 January 2021

RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways

1 reference

7 January 2021

The effect of non-enzymatic glycation of extracellular matrix proteins on axonal regeneration in vitro

1 reference

7 January 2021

Advanced glycation endproducts in peripheral nerve in type 2 diabetes with neuropathy

1 reference

7 January 2021

Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy

1 reference

7 January 2021

Assessing the outcome of the management of diabetic foot ulcers using ulcer-related and person-related measures

1 reference

7 January 2021

Glycosylation of low-density lipoprotein enhances cholesteryl ester synthesis in human monocyte-derived macrophages

1 reference

7 January 2021

RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes

1 reference

7 January 2021

RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice.

1 reference

7 January 2021

N(epsilon)-(carboxymethyl)lysine depositions in intramyocardial blood vessels in human and rat acute myocardial infarction: a predictor or reflection of infarction?

1 reference

7 January 2021

Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes

1 reference

7 January 2021

Advanced Glycation End Products and Antioxidant Status in Type 2 Diabetic Patients With and Without Peripheral Artery Disease

1 reference

7 January 2021

Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice

1 reference

7 January 2021

Intervention against the Maillard reaction in vivo

1 reference

7 January 2021

Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts

1 reference

7 January 2021

Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).

1 reference

7 January 2021

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy

1 reference

7 January 2021

Metformin inhibition of glycation processes

1 reference

7 January 2021

Pyridoxamine: the many virtues of a maillard reaction inhibitor.

1 reference

7 January 2021

Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage.

1 reference

7 January 2021

Crosslink breakers: a new approach to cardiovascular therapy

1 reference

7 January 2021

Collagen cross-link breakers: a beginning of a new era in the treatment of cardiovascular changes associated with aging, diabetes, and hypertension

1 reference

7 January 2021

Improved arterial compliance by a novel advanced glycation end-product crosslink breaker

1 reference

7 January 2021

The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure

1 reference

7 January 2021

Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process

1 reference

7 January 2021

Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension.

1 reference

7 January 2021

The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes.

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.861

1 reference

18 August 2017

1 reference